Ventus Therapeutics is a clinical-stage biopharmaceutical company leveraging a machine learning-enabled platform to advance a pipeline of novel medicines in immunology, inflammation, and neurology.

Ventus Therapeutics

Ventus Therapeutics | 14,098 followers on LinkedIn. Pioneering a unique approach to structure-based drug discovery. Located in Waltham, MA and Montreal, QC. | At Ventus, we are pioneering a unique approach to structure-based drug discovery to address biologically validated, but difficult-to-drug targets.

Others are building towards a future transformation of the drug development process … for Ventus, that future is already here.

Our ReSOLVE™ platform integrates cutting-edge, structurally enabled, computational tools to identify and perfect new drug molecules for targets which have never been drugged or for which existing chemical matter leaves significant room for improvement.

Managing Director at Versant Ventures

Jerel Davis

Associate Director DMPK, at Ventus Therapeutics

Amandine Chefson

Principal Scientist at Ventus Therapeutics

Sammy Kim

Biotech Executive; Board Member; R&D Leader; Physician Scientist; Mentor to Women and POC

Dolca Thomas, MD

Today, we shared results from the Phase 1 clinical trial of VENT-03, the first cGAS inhibitor to successfully complete a first-in-human study. In this trial, VENT-03 was safe and well-tolerated, showed a favorable PK profile that supports once-daily dosing, and demonstrated full target inhibition. These excellent results reinforce the significant potential of VENT-03 to be a first- and best-in-class oral anti-cGAS medication and emphasize the power of our ReSOLVE™ platform. Read and learn more: https://lnkd.in/eZahBgCv

We're going to #AIChE2024 ! Ventus' Nate Abraham, Ph.D. , Principal Scientist on our Computational Chemistry team, will present during the Computational Molecular Science and Engineering Forum poster session. Join us to connect and learn some interesting insights on protein preparation and protonation. Learn more below and at https://lnkd.in/eDj62kF5

Ventus' Head of Translational Sciences and Scientific Affairs, Kelly A. Pike , is in Avignon, France today presenting at the International Conference on Nucleic Acid Immunity 2024! We are thrilled to be among our industry peers as Kelly shares more about our first-in-class cGAS program, from the discovery to the development of VENT-03. Thank you, Kelly! Learn more at https://lnkd.in/ehx3emeB

It was an honor to be invited to present at the EMBO Inflammasome Workshop at Ludwig-Maximilians-Universität München in Munich. Our Chief Scientific Officer, Michael Crackower , presented our progress on the development of first-in-class caspase-4 inhibitors using our proprietary, biophysics-based and #machinelearning -enabled platform, ReSOLVE™. This is our first disclosure of our groundbreaking discovery of allosteric, selective, small-molecule caspase-4 inhibitors that are highly potent in vitro and in vivo and work via a previously undiscovered mechanism. The role of caspase-4 at the interface of bacterial components and the production of numerous cytokines makes this a highly compelling target for diseases of high unmet need like #InflammatoryBowelDisease , hidradenitis suppurative, and sepsis, where single cytokine inhibition has resulted in sub-optimal efficacy. Learn more about the power of our approach at https://www.ventustx.com/ and the event at https://lnkd.in/eGKQUFx7 .

The entire Ventus team met in Montreal at our new offices for an inspiring week of focus and collaboration. We dove deep into ongoing projects through cross-functional group discussions and productive working sessions. And of course, we made sure to balance hard work with some fun and team bonding. #VentusTx

Here at Ventus, we're able to do the work that really matters, aiming to quickly bring drugs to the clinic and significantly shorten the average drug discovery timeline from target identification to selection of a development candidate. Using our ReSOLVE™ platform, we can uniquely generate a blueprint for identifying and optimizing small molecule therapeutics. ReSOLVE™ is a proprietary, advanced, biophysics-based and #machinelearning -enabled platform that powers our discovery and development of small molecule medicines and guides our entire drug discovery process - ultimately leading to unique insights into protein targets for #immunology , #neurology and #inflammation . Learn more about ReSOLVE™ below and at Ventustx.com .

We enjoyed an awesome summer outing in Downtown Boston, where cityHUNT Scavenger Hunt put our local knowledge to the test with a fun day of scavenger hunting. Teams worked together to complete tasks and locate landmarks, fostering some friendly competition and a deeper appreciation for our corner of New England!

We are so excited to share that we've won BIOTECanada 's Gold Leaf Award 2024 for Promising Biotech Company of the Year! It's an honor to be recognized by BIOTECanada for the progress we've made in leveraging our #MachineLearning -enabled ReSOLVE™ platform to advance novel medicines, and we look forward to continuing this momentum. Thank you to our team, leaders, investors and partners for your dedication and support.

🎉 Celebrating the Best in Canadian Biotech! 🎉 The BIOTECanada Gold Leaf Awards celebrate the innovation and strengths fueling our biotech ecosystem. After receiving numerous nominations of outstanding individuals, companies, and organizations, we are proud to announce the 2024 winners. Their remarkable achievements will be honoured at BIONATION in September. Meet the winners: 🏆 Biotech Company of the Year: Aspect Biosystems 🏆Promising Biotech Company of the Year: Ventus Therapeutics 🏆Game-Changing Industry Leadership: Clarissa Desjardins 🏆Leadership Award: Peter Zandstra Thank you to the Gold Leaf Awards selection committee Shermaine Tilley ; Maxime Pesant CPA, CFA , Geneviève Guertin , John Norman , Penny Walsh-McGuire for their dedication and thoughtful review of this year's outstanding nominees. Read more about the Gold Leaf Awards, the categories, and the winners here: https://lnkd.in/eez5Mti6

BIOTECanada

“Our North Star is always going to be about developing therapeutics for people with high unmet needs who are suffering, “ said Ventus Chief Scientific Officer, Michael Crackower , on the most recent episode of Raising Health podcast. Dr. Crackower and Jason Burch joined Vineeta Agarwala, MD PhD, an a16z general partner, on Raising Health to discuss Ventus’ unique approach to #drugdiscovery through the power of water dynamics and our ReSOLVE™ platform. Listen below!

news impact assignment basic	general
public peers	general	Nov 11, 2024 9:15 PM	e8f4eef8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 11, 2024 9:15 PM	2e18fbf4
crunchbase trigger	general	Nov 11, 2024 9:15 PM	65cea888
crunchbase profile	general
li profile	general	Nov 11, 2024 9:15 PM	0dae3c93
translate crunchbase fundingrounds	general
peers	general	Nov 11, 2024 9:15 PM	494b3eda
news basic	general	Nov 11, 2024 9:15 PM	a22ba401
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

VENT

COM:VENTUSTX

Ventus Therapeutics